Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 31, Issue 41
  5. Article
Volume 31, Issue 41
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Introduction

Due to the confounding heterogeneity, the therapeutic strategy for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) remains to be defined.

Case Representation

We report a 38-year-old man with recurrent swelling of the eyelids and lower limbs, undergoing rituximab combined with steroid and tacrolimus treatment, who achieved an improved renal outcome. Underlying solid malignant tumours were excluded from the diagnosis.

Discussion

We treated patients with rituximab along with steroids and tacrolimus. Improvements in proteinuria and renal function were observed. We also reviewed the current literature to assess the efficacy of rituximab in the treatment of PGNMID.

Conclusion

However, a larger pool of patients and a longer follow-up period are required to establish the role of rituximab and steroids in the treatment of PGNMID.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673272183240108093135
2024-02-20
2024-11-20

  • From This Site

    /content/journals/cmc/10.2174/0109298673272183240108093135
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. NasrS.H. MarkowitzG.S. StokesM.B. SeshanS.V. ValderramaE. AppelG.B. AucouturierP. D’AgatiV.D. Proliferative glomerulonephritis with monoclonal IgG deposits: A distinct entity mimicking immune-complex glomerulonephritis.Kidney Int.2004651859610.1111/j.1523‑1755.2004.00365.x14675039
     [Google Scholar]
  2. NasrS.H. SatoskarA. MarkowitzG.S. ValeriA.M. AppelG.B. StokesM.B. NadasdyT. D’AgatiV.D. Proliferative glomerulonephritis with monoclonal IgG deposits.J. Am. Soc. Nephrol.20092092055206410.1681/ASN.200901011019470674
     [Google Scholar]
  3. NadaR. GowdaK.K. RamachandranR. JoshiK. TewariR. KohliH.S. JhaV. GuptaK.L. Proliferative glomerulonephritis with monoclonal immunoglobulin deposition disease: The utility of routine staining with immunoglobulin light chains.Indian J. Nephrol.201525634434810.4103/0971‑4065.15135426664209
     [Google Scholar]
  4. BridouxF. JavaugueV. NasrS.H. LeungN. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: A nephrologist perspective.Nephrol. Dial. Transplant.202136220821510.1093/ndt/gfz17633494099
     [Google Scholar]
  5. AucouturierP. D’AgatiV.D. RoncoP. A fresh perspective on monoclonal gammopathies of renal significance.Kidney Int. Rep.2021682059206510.1016/j.ekir.2021.04.02634386655
     [Google Scholar]
  6. BarbourS.J. BeaulieuM.C. ZalunardoN.Y. MagilA.B. Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases.Nephrol. Dial. Transplant.20112682712271410.1093/ndt/gfr25121633102
     [Google Scholar]
  7. NasrS.H. SethiS. CornellL.D. FidlerM.E. BoelkinsM. FervenzaF.C. CosioF.G. D’AgatiV.D. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft.Clin. J. Am. Soc. Nephrol.20116112213210.2215/CJN.0575071020876681
     [Google Scholar]
  8. TsujiT MiuraM YanaiM De novo proliferative glomerulonephritis with monoclonal IgG deposits of the IgG1kappa subtype in a kidney allograft.Nephrology201621S14447
     [Google Scholar]
  9. MerhiB. PatelN. BaylissG. HenriksenK.J. GohhR. Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab.Clin. Kidney J.201710340541010.1093/ckj/sfx00128616219
     [Google Scholar]
  10. TorrealbaJ. GattineniJ. HendricksA.R. Proliferative glomerulonephritis with monoclonal immunoglobulin G lambda deposits: Report of the first pediatric case.Case Rep. Nephrol. Dial.201881707510.1159/00048864129850460
     [Google Scholar]
  11. XingG. GillespieR. BedriB. QuanA. ZhangP. ZhouX.J. Proliferative glomerulonephritis with monoclonal IgG deposits in children and young adults.Pediatr. Nephrol.20183391531153810.1007/s00467‑018‑3949‑829616329
     [Google Scholar]
  12. MaanD. ClarkB. BunkerM. AroraS. Successful management of proliferative glomerulonephritis with monoclonal immune deposits with combined immunosuppressive therapy.BMJ Case Rep.2018111e22520510.1136/bcr‑2018‑22520530567197
     [Google Scholar]
  13. WenJ. WangW. XuF. ChenJ. ZhangM. ChengD. NiX. LiX. LiuZ. Clinicopathological analysis of proliferative glomerulonephritis with monoclonal IgG deposits in 5 renal allografts.BMC Nephrol.201819117310.1186/s12882‑018‑0969‑329996809
     [Google Scholar]
  14. GumberR. CohenJ.B. PalmerM.B. KobrinS.M. VoglD.T. WassersteinA.G. NastaS.D. BleicherM.B. BloomR.D. DemberL. CohenA. WeissB.M. HoganJ.J. A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.Kidney Int.201894119920510.1016/j.kint.2018.02.02029759418
     [Google Scholar]
  15. SawadaA KawanishiK HoritaS Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.Nephrology201621S14852
     [Google Scholar]
  16. BuxedaA. SaidS.M. NasrS.H. LeungN. El TersM. CosioF.G. Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-CD20 antibodies.Transplantation201910371477148510.1097/TP.000000000000257730747850
     [Google Scholar]
  17. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work GroupKDIGO 2021 clinical practice guideline for the management of glomerular diseases.Kidney Int.20211004SS1S27634556256
     [Google Scholar]
  18. LiY. FuR. GaoJ. WangL. DuanZ. TianL. GeH. MaX. ZhangY. LiK. XuP. TianX. ChenZ. Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: A 18-month prospective clinical trial.Sci. Rep.202212125510.1038/s41598‑021‑03691‑034996948
     [Google Scholar]
  19. ZhaoJ. MaF. BaiM. SunS. Low-dose corticosteroid combined with mycophenolate mofetil for IgA Nephropathy with stage 3 or 4 CKD: A retrospective cohort study.Clin. Ther.202143585987010.1016/j.clinthera.2021.03.00933863547
     [Google Scholar]
  20. ShengyouY. LiY. ZhihongH. YuanyuanM. Influence of tacrolimus on podocyte injury inducted by angiotensin II.J. Renin Angiotensin Aldosterone Syst.201516226026610.1177/147032031456852025650384
     [Google Scholar]
  21. ZhangS. WangH. LiuY. YangW. LiuJ. HanY. LiuY. LiuF. SunL. XiaoL. Tacrolimus ameliorates tubulointerstitial inflammation in diabetic nephropathy via inhibiting the NFATc1/TRPC6 pathway.J. Cell. Mol. Med.202024179810982410.1111/jcmm.1556232779844
     [Google Scholar]
  22. MaR WangY XuY. Tacrolimus protects podocytes from apoptosis via downregulation of TRPC6 in diabetic nephropathy.J. Diabetes. Res2021883211434095318PMC8163546
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673272183240108093135
Loading
Rituximab Combined with Steroid and Tacrolimus Treats Proliferative Glomerulonephritis with Monoclonal IgG Deposits: A Case Report and Review of the Literature
Curr. Med. Chem. 31, 6902 (2024); https://doi.org/10.2174/0109298673272183240108093135
/content/journals/cmc/10.2174/0109298673272183240108093135
/content/journals/cmc/10.2174/0109298673272183240108093135
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): case report; Proliferative glomerulonephritis with monoclonal IgG deposits; renal outcome; rituximab; steroids; tacrolimus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test